We recently compiled a list of the 10 Firms End Trading Week Defying Market Bloodbath. In this article, we are going to take ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

Argus has recently raised Teva Pharmaceutical Industries Ltd (TEVA) stock to Buy rating, as announced on July 10, 2024, according to Finviz. Earlier, on March 8, 2024, JP Morgan had raised the stock ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.24 which represents a decrease of $-0.06 or -0.28% from the prior close of $21.3. The stock opened at $21.4 and ...

TEV-56278 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Solid Tumor.

Shares of Catalyst Pharmaceuticals (CPRX) have resumed trading and are higher after the company announced that the company and its licensor ...

Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here ...

NYSE:TEVA opened at $22.62 on Friday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.39 and a ...

TEV-56192 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Unspecified Neurologic Disorders.

In this article, we are going to take a look at where Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stands against the other stocks. A wave of selling gripped Wall Street this Friday, pushing ...

Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.